Wednesday, January 9, 2019
Amarin CEO hints at stronger 2019 outlook for Vascepa sales
Amarin CEO John Thero dropped hints at his breakout session at the JPMorgan Healthcare conference that the comapny has a stronger 2019 outlook for Vascepa than its official guidance offered a week ago, STAT News reports. Though Thero can’t say directly that he expects better sales, he not-so-subtly suggested a stronger sales outlook for the heart drug, the report says
https://thefly.com/landingPageNews.php?id=2846463
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.